Clinical Trials Browser

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase 1/2 Completed

89 enrolled 21 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04487847 2025-01-16

PICture

Phase 1/2 Completed

75 enrolled

Genitourinary

Prostatic Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

126 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT06398470 2025-01-10

Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy

Phase 1/2 Completed

21 enrolled

Genitourinary

Margins of Excision, Prostatic Neoplasms

NCT01784913 2024-12-16

UV1/hTERT2012P

Phase 1/2 Completed

22 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01774071 2024-10-02

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Phase 1/2 Completed

19 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT01685268 2024-08-02

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Phase 1/2 Completed

49 enrolled

Genitourinary

Prostatic Neoplasms

NCT02933255 2024-05-31

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Phase 1/2 Completed

24 enrolled 20 charts

Genitourinary

Prostatic Neoplasms

NCT02555189 2024-05-13

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Completed

46 enrolled

Genitourinary

Prostatic Neoplasms

NCT04742959 2024-04-26

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Phase 1/2 Completed

203 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02325557 2024-04-02

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Completed

50 enrolled 14 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00946881 2024-02-07

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Phase 1/2 Completed

30 enrolled 12 charts

Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00915122 2023-12-06

Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate

Phase 1/2 Completed

81 enrolled

Genitourinary

Prostatic Neoplasms

NCT03513211 2023-11-22

HITMAN-PC

Phase 1/2 Completed

12 enrolled

Genitourinary

Prostatic Neoplasms

NCT05516329 2023-09-21

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

Phase 1/2 Completed

49 enrolled

Genitourinary

Prostatic Neoplasms

NCT04614363 2023-08-28

68 Ga-PSMA for High Risk Prostate Cancer

Phase 1/2 Completed

80 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Phase 1/2 Completed

49 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Tonsillar Neoplasms, Urologic Neoplasms, Carcinoma, Mucoepidermoid, Cholangiocarcinoma, Rare Diseases

NCT02499835 2023-08-01

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Phase 1/2 Completed

66 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT01278914 2023-05-08

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer

Phase 1/2 Completed

Genitourinary

Prostatic Neoplasms

NCT00547339 2022-12-07

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1/2 Completed

94 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

Phase 1/2 Completed

61 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT04685811 2022-09-22

Evaluation of PSMA Antagonist Produced by Two Different Methods

Phase 1/2 Completed

16 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1/2 Completed

43 enrolled 22 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02012296 2022-07-13

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Phase 1/2 Completed

88 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT01861496 2022-02-24

LiPlaCis

Phase 1/2 Completed

50 enrolled

DermatologicGenitourinary

Prostatic Neoplasms, Skin Neoplasms

NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1/2 Completed

195 enrolled 51 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT02711956 2021-11-30

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

75 enrolled 31 charts

Genitourinary

Prostatic Neoplasms

NCT02280317 2021-11-08

VAL201-001

Phase 1/2 Completed

12 enrolled 16 charts

Genitourinary

Prostatic Neoplasms

NCT04555343 2021-11-05

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Phase 1/2 Completed

14 enrolled

Genitourinary

Urinary Bladder Neoplasms, Hematuria, Prostatic Neoplasms, Urologic Diseases, Urinary Retention, Patient Satisfaction

NCT01868386 2021-04-28

HypoFX

Phase 1/2 Completed

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT02552121 2021-04-08

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1/2 Completed

33 enrolled 70 charts

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT01317199 2021-04-02